| Prev Close | 7.38 |
| Open | 7.32 |
| Day Low/High | 7.03 / 7.48 |
| 52 Wk Low/High | 6.15 / 11.34 |
| Volume | 12.62K |
| Avg Volume | 26.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 14.44M |
| Market Cap | 104.13M |
| EPS | -0.80 |
| P/E Ratio | 9.43 |
| Div & Yield | N.A. (N.A) |
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
These under-$10 stocks are within range of triggering breakout trades.
These under-$10 stocks are within range of triggering big breakout trades.
This beaten-down biotech stock could be ripe for a rebound.
Insiders at these companies have been scooping up shares of their own stock lately.
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:
![[video] Quick Take: Revolutionizing Diabetes Treatment](http://s.thestreet.com/files/tsc/v2008/photos/all-pics/rx/doctor-patient-139x90.jpg)
This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.
This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.
Marking a major milestone for the company, Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( http://www.
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( www.
SmallCapVoice.com, Inc.
